Results 31 to 40 of about 30,408 (190)

Bedaquiline Drug Resistance Emergence Assessment in MDR-TB (DREAM): a 5-year prospective in-vitro surveillance study of bedaquiline and other second-line drug-susceptibility testing in MDR-TB isolates / [PDF]

, 2021
Bedaquiline Drug Resistance Emergence Assessment in Multidrug-resistant-tuberculosis (MDR-TB) (DREAM) was a 5-year (2015–2019) phenotypic drug-resistance surveillance study across 11 countries. DREAM assessed the susceptibility of 5036 MDR-TB isolates of
Vasiliauskaitė, Laima,, Tahseen, Sabira, Jou, Ruwen, Shin, Soyoun, Shin, Soyoun,, Musteikiene, Greta, Smithtikarn, Saijai,, Chuchottaworn, Charoen, Miliauskas, Skaidrius, Wu, Mei-Hua,, Simsek, Hulya,, Sacopon, Catherine Ann, Ismail, Nazir, Miliauskas, Skaidrius,, Rodrigues, Camilla, Metchock, Beverly,, Rodrigues, Camilla,, Vasiliauskaitė, Laima, Jou, Ruwen,, Vasiliauskienė, Edita, Kaniga, Koné, Viet Nhung, Nguyen, Kaniga, Koné,, Simsek, Hulya, Boonyasopun, Jirakan, Hasan, Rumina, Tahseen, Sabira,, Kazi, Mubin,, Metchock, Beverly, Kamolwat, Phalin, Kazi, Mubin, Boonyasopun, Jirakan,, Wu, Mei-Hua, Musteikienė, Greta,, Vally Omar, Shaheed,, Kim, Seungmo, Vally Omar, Shaheed, Viet Nhung, Nguyen,, Hasan, Rumina,, Kim, Seungmo,, Ngoc, Anh Le Thi, Ismail, Nazir,, Ngoc, Anh Le Thi,, Kamolwat, Phalin,, Smithtikarn, Saijai, Chuchottaworn, Charoen,, Vasiliauskienė, Edita,, Sacopon, Catherine Ann,   +47 more
core   +2 more sources

Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases

BMC Infectious Diseases, 2019
Background Bedaquiline was recently introduced into World Health Organization (WHO)-recommended regimens for treatment of drug resistant tuberculosis. There is limited data on the long-term safety of bedaquiline.
Jackie Jones, Vanessa Mudaly, Jacqueline Voget, Tracey Naledi, Gary Maartens, Karen Cohen   +5 more
doaj   +1 more source

Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies. [PDF]

Br J Clin Pharmacol
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Maria N, Larasati AL, Hamdani IY, Cho JG, Alffenaar JC.   +4 more
europepmc   +2 more sources

Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report

Brazilian Journal of Infectious Diseases, 2022
Introduction: Spinal Tuberculosis (STB) represents between 1% and 2% of total tuberculosis cases. STB management remains challenging; the first-line approach consists of medical treatment, while surgery is reserved for patients with complications.
Andrea De Vito, Vito Fiore, Valentina Urru, Elena Bozzi, Nicholas Geremia, Elija Princic, Donatella Canu, Paola Molicotti, Riccardo Are, Sergio Babudieri, Giordano Madeddu   +10 more
doaj   +1 more source

A Bayesian approach to estimate the probability of resistance to bedaquiline in the presence of a genomic variant.

PLoS ONE, 2023
BackgroundBedaquiline is a core drug for treatment of rifampicin-resistant tuberculosis. Few genomic variants have been statistically associated with bedaquiline resistance.
Degefaye Zelalem Anlay, Emmanuel Rivière, Pham Hien Trang Tu, Steven Abrams, Annelies Van Rie   +4 more
doaj   +1 more source

Bedaquiline-associated parameter ranges.

, 2016
Bedaquiline-associated parameter ranges.
Frank G. Cobelens (629970), Amber Kunkel (3208332), Ted Cohen (118302)   +2 more
core   +1 more source

Bedaquiline and clofazimine : successes and challenges [PDF]

, 2020
Bedaquiline, a novel therapeutic drug, and clofazimine, a re-purposed drug, are front-line therapies recommended by WHO to treat rifampicin-resistant or multidrugresistant tuberculosis.
Ndjeka, Norbert, Ismail, Nazir Ahmed
core   +1 more source

Inhibitory effect of carvedilol on bedaquiline metabolism in vitro and in vivo [PDF]

PeerJ
Bedaquiline has recently been approved for the treatment of multidrug-resistant tuberculosis. Carvedilol is a cardiovascular medication extensively used in the treatment of heart failure and hypertension.
Qingqing Li, Wanshu Li, Jie Chen, Hangjuan Lin, Cixia Zhou   +4 more
doaj   +2 more sources

Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients [PDF]

, 2020
Genetic mutations linked to bedaquiline resistance were found before starting treatment and acquired during treatment in patients with drug-resistant TB and HIV in KwaZulu-Natal, South Africa.
Grant, Alison D, Brien, Kayleen, van Dorp, L, Nimmo, Camus, Nimmo, C, Millard, James, Pym, AS, Pym, Alexander S, van Dorp, Lucy, Lutchminarain, K, Balloux, F, Moodley, S, Wolf, A, O'Donnell, M, Padayatchi, Nesri, Padayatchi, N, Brien, K, Balloux, Francois, Grant, AD, Lutchminarain, Keeren, O'Donnell, Max, Moodley, Sashen, Wolf, Allison, Millard, J   +23 more
core   +1 more source

Genetic variants and their association with phenotypic resistance to bedaquiline in Mycobacterium tuberculosis: a systematic review and individual isolate data analysis

The Lancet Microbe, 2021
Summary: Background: Bedaquiline is a crucial drug for control of rifampicin-resistant tuberculosis. Molecular drug resistance assays could facilitate effective use of bedaquiline and surveillance of drug resistance emergence.
Nabila Ismail, PhD, Emmanuel Rivière, MSc, Jason Limberis, PhD, Stella Huo, MSc, John Z Metcalfe, ProfPhD, Rob M Warren, ProfPhD, Annelies Van Rie, ProfPhD   +6 more
doaj   +1 more source